Phase I Feasibility Study of ALLOSTIM(TM) in Combination With Radiofrequency Ablation in Patients With Refractory Hepatocellular Carcinoma

Trial Profile

Phase I Feasibility Study of ALLOSTIM(TM) in Combination With Radiofrequency Ablation in Patients With Refractory Hepatocellular Carcinoma

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 10 Dec 2015

At a glance

  • Drugs T-cell vaccine-AlloStim (Primary) ; T-cell vaccine-AlloStim (Primary) ; T-cell vaccine-AlloStim (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Sponsors Immunovative Therapies
  • Most Recent Events

    • 01 Apr 2015 According to the ClinicalTrials.gov record, status changed from not yet recruiting to withdrawn prior to enrolment.
    • 03 Jan 2014 Planned initiation date changed from 1 Nov 2013 to 1 Jan 2014, as reported in a Tauriga Sciences media release.
    • 20 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top